NCT03444311 is a NA clinical trial of A: 1 dosis in Colitis, Ulcerative, sponsored by AB Biotics, SA.

Who is sponsoring NCT03444311?

NCT03444311 is sponsored by AB Biotics, SA.

What drugs are being tested in NCT03444311?

Interventions in NCT03444311: A: 1 dosis, B: 2 dosis.

What condition does NCT03444311 study?

NCT03444311 studies Colitis, Ulcerative.

Is NCT03444311 still recruiting?

NCT03444311 is currently terminated. Last updated 8 July 2020.

Last reviewed 2020-07-08 · How we verify

NCT03444311

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combined Nutritional Therapies for the Treatment of Ulcerative Colitis

Terminated NA Last updated 8 July 2020

What this trial tests

NA trial testing A: 1 dosis in Colitis, Ulcerative in 12 participants. Terminated before completion.

Timeline

8 March 2018

Primary endpoint
2 July 2019

2 July 2020

Quick facts

Lead sponsor	AB Biotics, SA
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	8 March 2018
Primary completion	2 July 2019
Estimated completion	2 July 2020
Sites	1 location across Spain

Drugs / interventions tested

A: 1 dosis
B: 2 dosis

Conditions studied

Colitis, Ulcerative — all drugs for Colitis, Ulcerative →

Sponsor

AB Biotics, SA — full company profile →

Who can join

Adults 18 to 65, any sex, with Colitis, Ulcerative. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ulcerative colitis (UC) is an entity of complex etiology where environmental, genetic and intestinal microflora-related factors trigger and perpetuate a chronic inflammation of the gastrointestinal tract. It is suspected that an alteration in primary intestinal microbial colonization (dysbiosis) could trigger, or at least contribute to, said oversized immune response. The hypothesis is that the administration of a series of fibers, could improve the bacterial diversity and repair the dysbiosis that has been seen in patients affected by ulcerative colitis, improving the clinical evolution of it. The primary objective of the present study is to know the impact on the microbiota of patients with UC in remission derived from the administration of dietary fibers. The RETOS study is a pilot project in which a population of patients with UC is tested for the effect on the composition of the microbiota that would have the administration of various combinations of fibers, in addition to the tolerability and acceptance by the patient. The clinical applicability derived from this intervention would be to improve the diversity of intestinal flora of patients with ulcerative colitis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

β-Glucan Metabolic and Immunomodulatory Properties and Potential for Clinical Application.
Murphy EJ, Rezoagli E, Major I, Rowan NJ, et al · · 2020 · cited 121× · PMID 33322069 · DOI 10.3390/jof6040356

Verify or expand the search:

Other recruiting trials for Colitis, Ulcerative

Currently open trials in the same condition.

NCT07302360 — A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis · recruiting
NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea · recruiting
NCT07196748 — A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Col · Phase 3 · recruiting
NCT07102368 — A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany · recruiting
NCT06651281 — Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Coli · Phase 3 · recruiting

Other AB Biotics, SA trials

Trials by the same sponsor.

NCT07193927 — Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Diseas · Phase 2 · not yet recruiting
NCT06604234 — Impact of a Probiotic Combination on Quality of Life and Symptoms in Peri- and Postmenopausal Women · NA · completed
NCT06193096 — Impact of a Probiotic-based Formula on Digestive Symptoms and Mood in Ultra Marathon Runners · NA · completed
NCT05688397 — Evaluation of the Vaginal Colonization of Two New Lactobacillus Strains After Oral Administration in Healthy Volunteers · NA · completed
NCT05524649 — Effect of Probiotics on Infant's Fecal Microbiota Composition · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03444311 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AB Biotics, SA
Last refreshed: 8 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03444311.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing